Novo Nordisk will issue 340B provider refunds for formulations of two hemophilia drugs, according to a HRSA manufacturer notice.

Novo Nordisk to Provide 340B Refunds on Hemophilia Drugs

Novo Nordisk will issue its fifth round of refunds this year on prices charged to 340B providers. The latest are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at